Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.58 |
| ▸ | BCR | P11274 | 6/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | PRKCA | P17252 | 1/20 | 0.58 |
| ▸ | KIT | P10721 | 6/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938869 | 0.87 | ABL1 (0.55) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2944349 | 0.87 | ABL1 (0.55) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2945044 | 0.86 | ABL1 (0.61) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2941616 | 0.85 | KIT (0.61) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL3219611 | 0.79 | PDGFRA (0.83) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2947554 | 0.79 | PRKCA (0.45) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2944346 | 0.79 | ABL1 (0.57) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2939690 | 0.77 | ABL1 (0.60) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL3973176 | 0.76 | ABL1 (0.82) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL4899644 | 0.76 | ABL1 (0.63) | ABL1PDGFRABCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635835-B1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | NOVARTIS AG (CH) | 2006-12-28 | — | — | US | disclosed |
| EP-1635835-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110452-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | ABL1 72/4885PDGFRA 881/4885BCR 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.